Scalp psoriasis products occupy a critical regulatory boundary between cosmetics and drugs, and the rules differ significantly by region, which directly impacts your formulation strategy and claim-making. In the United States, the FDA classifies scalp psoriasis products as cosmetics if they make no drug claims (e.g., 'cleanses' or 'conditions') but as drugs if they claim to treat, mitigate, or prevent psoriasis itself. This means your product can contain non-monograph actives like salicylic acid (a cosmetic ingredient in lower concentrations) or botanical soothing agents, but you cannot claim 'treats psoriasis' or 'reduces inflammation associated with psoriasis'—those claims trigger drug classification and require clinical data, IND approval, and much longer timelines. Coal tar, though controversial, remains a cosmetic-permissible ingredient under FDA guidelines when used within defined concentration limits. In the European Union, the Cosmetics Regulation (EC 1223/2009) is stricter: certain actives used in scalp psoriasis products (including some coal tar derivatives and zinc pyrithione above specific concentrations) require notified safety assessments and may be restricted entirely in some member states. EU brands often formulate around these limits by emphasizing botanical actives and mechanical exfoliation rather than chemical actives. Canada's Natural and Non-prescription Health Products Directorate (NNHPD) treats scalp psoriasis products similarly to the US but with additional emphasis on botanical ingredient dossiers if you make any wellness claims. Australia's TGA classifies products based on stated purpose: a 'scalp treatment' with soothing claims is cosmetic, but 'psoriasis relief' becomes therapeutic and requires different approval pathways. The UK, post-Brexit, has adopted its own Cosmetics Regulations which largely mirror the EU but with ongoing divergence in coal tar and zinc pyrithione allowances. When you hire a chemist via AJ Cosmo Labs, confirm that your formulator understands not just your target market's regulatory framework but also how claim restrictions shape ingredient selection. A formulation suitable for a US-only launch may require complete reformulation for EU distribution. Most founders underestimate regional compliance costs: budget for regulatory dossier preparation, pre-market notification or registration (where required), and often third-party claims substantiation testing. Your chemist should provide a regulatory roadmap in their proposal that maps actives, concentrations, and permissible claims to each target region. Failure to clarify this early leads to costly pivot during manufacturing or, worse, post-launch compliance action.
Ingredients in this answer: Salicylic Acid
Read the full guide on How to Find a Cosmetic Chemist for Scalp Psoriasis Products →